SHINE 2

  • Research type

    Research Study

  • Full title

    SHINE-2: Screening the Hips in Newborns. The Use of an Acoustic Device to Identify Developmental Hip Dysplasia in Babies

  • IRAS ID

    324933

  • Contact name

    Daniel Perry

  • Contact email

    danperry@liverpool.ac.uk

  • Sponsor organisation

    University of Liverpool

  • Duration of Study in the UK

    1 years, 11 months, 30 days

  • Research summary

    Developmental dysplasia of the hip (DDH) is a spectrum of disease. One per 1000 babies have a frankly dislocated hip, and 2-3% are diagnosed with some degree of hip dysplasia(1). DDH is associated with premature osteoarthritis and is the reason for 10% of all hip replacements, and is the most commonly identified cause of hip osteoarthritis in those under 60 years old(2). Early diagnosis is crucial to determine whether surgery is required in childhood, and to maximise outcomes in adulthood. If DDH is identified early in infancy, it can usually be rectified with a removable splint, worn for just a few weeks.

    The UK uses a nationwide selective ultrasound screening programme for DDH(3). Clinical examination is universal and if abnormal, is followed by ultrasound screening. Clinical examination involves several screening manoeuvres, which the National Screening Committee (NSC) acknowledges are poor tests, as they are difficult to teach, difficult to monitor or assess competence, and have high variability amongst clinicians. The NSC estimates that around two in three hip dislocations are missed on screening(4).

    The alternative approach is universal ultrasound screening, which is practiced in some parts of mainland Europe. A Cochrane review has highlighted the costly nature of the alternative and high levels of false positives that this would generate(5). The NSC therefore does not recommend universal ultrasound screening, opting for the current selective screening model acknowledging the flaws. A new screening tool is needed, which that better fulfils the Wilson and Jungner criteria for screening(6), i.e. the test needs to be simple, safe, precise, validated and cost-effective – and one that ideally is reproducible even with minimal training.

    Through a prior study (SHINE), we have demonstrated sound transmission to be an effective tool to identify infant hips that are dislocated. SHINE2 will develop the techniques to refine the screening tool, to progress the technology to Technology Readiness Level (TRL) 4. Alongside this, we will demonstrate the market opportunities for such a device and develop a health economic model to demonstrate the potential value of the tool to society. We will also engage with industry, whilst protecting any IP generated. It is anticipated that SHINE2 will bring the device to the point that the technology is finalised, and a commercial product can be conceived.

  • REC name

    HSC REC A

  • REC reference

    23/NI/0066

  • Date of REC Opinion

    26 Jun 2023

  • REC opinion

    Further Information Favourable Opinion